mosliciguat

Mosliciguat is a first-in-class, inhaled small molecule soluble guanylate cyclase (sGC) activator developed for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). Unlike sGC stimulators, which require reduced heme and nitric oxide (NO) to activate sGC, mosliciguat directly activates both native and oxidized/heme-free forms of sGC independently of NO and heme. This mechanism allows it to restore sGC function even in conditions characterized by oxidative stress where NO levels are depleted and heme is oxidized or removed. By activating sGC, mosliciguat increases cyclic guanosine monophosphate (cGMP) production in the lungs, leading to vasodilation as well as potential anti-inflammatory and anti-fibrotic effects. The drug is administered via a dry powder inhaler for targeted delivery to the lungs with once-daily dosing. Mosliciguat has shown promising results in early clinical trials for reducing pulmonary vascular resistance in PH-ILD patients[1][2][3][6][8].

Other names

mosliciguatBAY1237592BAY-1237592BAY 1237592